Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement activation and hypersensitivity reactions to dialysis membranes.

R M Hakim, J Breillatt, J M Lazarus

    The New England Journal of Medicine
    |October 4, 1984
    PubMed
    Summary

    Patients undergoing hemodialysis with new cuprophane membranes may experience the "first-use syndrome." This study links these adverse reactions to complement activation, a key immune response.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Predictors of liver donation without kidney recovery in a cohort of expanded criteria donors: identifying opportunities to improve expanded criteria donor kidney utilization.

    Transplantation proceedings·2012
    Same author

    Transplanting kidneys without points for HLA-B matching: consequences of the policy change.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
    Same author

    Toward a continuous quality improvement paradigm for hemodialysis providers with preliminary suggestions for clinical practice monitoring and measurement.

    Hemodialysis international. International Symposium on Home Hemodialysis·2009
    Same author

    Trends in organ donation and transplantation in the United States, 1998-2007.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009
    Same author

    Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA.

    American journal of nephrology·2008
    Same author

    Trends in organ donation and transplantation in the United States, 1997-2006.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2008

    Area of Science:

    • Immunology
    • Nephrology
    • Biochemistry

    Background:

    • Hemodialysis patients can develop adverse reactions, termed
    • first-use syndrome,
    • when exposed to new cuprophane membranes.
    • Complement activation is a potential mechanism underlying these acute symptoms.

    Observation:

    • In vivo complement activation was assessed during hemodialysis with new cuprophane membranes.
    • In vitro complement activation was studied using zymosan in patients with and without the first-use syndrome.

    Findings:

    • Patients with the first-use syndrome exhibited significantly higher levels of C3a des-arginine (C3a desArg), a marker of complement activation, both in vivo and in vitro compared to asymptomatic individuals.
    • Maximal in vivo complement activation occurred earlier (10 minutes) in symptomatic patients.

    Related Experiment Videos

  • Severe adverse events, including cardiopulmonary collapse, were associated with markedly elevated C3a desArg levels.

    • Implications:

    • These findings strongly correlate adverse symptoms during hemodialysis with new cuprophane membranes to complement activation.
    • Understanding this link may guide strategies to mitigate or prevent first-use syndrome in hemodialysis patients.
    • Further research could explore alternative membrane materials or pre-treatment protocols to reduce complement-mediated reactions.